Novo Nordisk A/S (NONOF)
OTCMKTS
· Delayed Price · Currency is USD
67.00
+0.60 (0.90%)
May 12, 2025, 12:20 PM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 78.09B DKK in the quarter ending March 31, 2025, with 19.49% growth. This brings the company's revenue in the last twelve months to 303.14B, up 24.11% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
303.14B DKK
Revenue Growth
+24.11%
P/S Ratio
6.65
Revenue / Employee
3.92M DKK
Employees
77,349
Market Cap
292.03B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Novo Nordisk News
- 1 hour ago - Novo Nordisk: A Strategy With High Potential For Volatile Times - Seeking Alpha
- 12 hours ago - 50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy - Seeking Alpha
- 14 hours ago - Trump calls out weight-loss drugs as target of price-cut push - Reuters
- 15 hours ago - Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know - CNBC
- 18 hours ago - Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet - Seeking Alpha
- 21 hours ago - Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders - Benzinga
- 22 hours ago - Novo Nordisk Stock Is Slumping Today. Here's Why. - Barrons
- 1 day ago - Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial - Seeking Alpha